Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane

A. K. Hubbard, T. P. Roth, A Jay Gandolfi, B. R. Brown, N. R. Webster, J. F. Nunn

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The current work presents evidence that five of six patients with HH have a high titer of circulating antibody that recognizes the reactive intermediate of halothane (TFA), whereas ten patients exposed to halothane and not developing HH have minimal or no levels of this antibody. This paper, then, explores the association between titer/chronology of the anti-TFA antibody response and indicators/predisposing factors of halothane hepatitis in these patients with HH to determine if a cause (immune response)-and-effect (hepatotoxicity) relationship exists. Although the data presented here do not yet support a role for this humoral immune response in mediating liver damage, it is clear that, in patients developing unexplained hepatitis following halothane exposure, a persistent anti-TFA antibody response is elicited.

Original languageEnglish (US)
Pages (from-to)791-796
Number of pages6
JournalAnesthesiology
Volume68
Issue number5
StatePublished - 1988

Fingerprint

Halothane
Antibody Formation
Anti-Idiotypic Antibodies
Chronology
Antibodies
Humoral Immunity
Causality
Halothane Hepatitis
Liver

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Hubbard, A. K., Roth, T. P., Gandolfi, A. J., Brown, B. R., Webster, N. R., & Nunn, J. F. (1988). Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. Anesthesiology, 68(5), 791-796.

Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. / Hubbard, A. K.; Roth, T. P.; Gandolfi, A Jay; Brown, B. R.; Webster, N. R.; Nunn, J. F.

In: Anesthesiology, Vol. 68, No. 5, 1988, p. 791-796.

Research output: Contribution to journalArticle

Hubbard, AK, Roth, TP, Gandolfi, AJ, Brown, BR, Webster, NR & Nunn, JF 1988, 'Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane', Anesthesiology, vol. 68, no. 5, pp. 791-796.
Hubbard, A. K. ; Roth, T. P. ; Gandolfi, A Jay ; Brown, B. R. ; Webster, N. R. ; Nunn, J. F. / Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane. In: Anesthesiology. 1988 ; Vol. 68, No. 5. pp. 791-796.
@article{d86949c810bb46b59b4bd48672d91be5,
title = "Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane",
abstract = "The current work presents evidence that five of six patients with HH have a high titer of circulating antibody that recognizes the reactive intermediate of halothane (TFA), whereas ten patients exposed to halothane and not developing HH have minimal or no levels of this antibody. This paper, then, explores the association between titer/chronology of the anti-TFA antibody response and indicators/predisposing factors of halothane hepatitis in these patients with HH to determine if a cause (immune response)-and-effect (hepatotoxicity) relationship exists. Although the data presented here do not yet support a role for this humoral immune response in mediating liver damage, it is clear that, in patients developing unexplained hepatitis following halothane exposure, a persistent anti-TFA antibody response is elicited.",
author = "Hubbard, {A. K.} and Roth, {T. P.} and Gandolfi, {A Jay} and Brown, {B. R.} and Webster, {N. R.} and Nunn, {J. F.}",
year = "1988",
language = "English (US)",
volume = "68",
pages = "791--796",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Halothane hepatitis patients generate an antibody response toward a covalently bound metabolite of halothane

AU - Hubbard, A. K.

AU - Roth, T. P.

AU - Gandolfi, A Jay

AU - Brown, B. R.

AU - Webster, N. R.

AU - Nunn, J. F.

PY - 1988

Y1 - 1988

N2 - The current work presents evidence that five of six patients with HH have a high titer of circulating antibody that recognizes the reactive intermediate of halothane (TFA), whereas ten patients exposed to halothane and not developing HH have minimal or no levels of this antibody. This paper, then, explores the association between titer/chronology of the anti-TFA antibody response and indicators/predisposing factors of halothane hepatitis in these patients with HH to determine if a cause (immune response)-and-effect (hepatotoxicity) relationship exists. Although the data presented here do not yet support a role for this humoral immune response in mediating liver damage, it is clear that, in patients developing unexplained hepatitis following halothane exposure, a persistent anti-TFA antibody response is elicited.

AB - The current work presents evidence that five of six patients with HH have a high titer of circulating antibody that recognizes the reactive intermediate of halothane (TFA), whereas ten patients exposed to halothane and not developing HH have minimal or no levels of this antibody. This paper, then, explores the association between titer/chronology of the anti-TFA antibody response and indicators/predisposing factors of halothane hepatitis in these patients with HH to determine if a cause (immune response)-and-effect (hepatotoxicity) relationship exists. Although the data presented here do not yet support a role for this humoral immune response in mediating liver damage, it is clear that, in patients developing unexplained hepatitis following halothane exposure, a persistent anti-TFA antibody response is elicited.

UR - http://www.scopus.com/inward/record.url?scp=0023896917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023896917&partnerID=8YFLogxK

M3 - Article

C2 - 3369720

AN - SCOPUS:0023896917

VL - 68

SP - 791

EP - 796

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 5

ER -